Key facts
- This page summarizes Christopher Ryan Sullivan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 Oct 2022, 16:01.
Christopher Ryan Sullivan - 05 Oct 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- AVTX
- Reported as of
- 05 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Oct 2022, 16:01:47 UTC
- Prior SEC filing
- 10 Mar 2022
- Next SEC filing
- 15 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Zoltoski, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Ryan Sullivan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 07 Oct 2022.
Change
- Previous filing in this sequence was filed on 10 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 05 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $3.97
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date.